



DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Novel Drug and Medical Device Development Tools to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders

Date: March 6, 2023

Time: 3:00 PM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-5819
gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Developing Digital Therapeutics for Substance Use Disorders

Date: March 13, 2023

Time: 11:00 AM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Jenny Raye Browning, Ph.D.
Scientific Review Officer
Scientific Review Branch
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021

Bethesda, MD 20892
(301) 443-4577
jenny.browning@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Pharmacokinetic and Pharmacodynamic Trials for Medication Development in Substance Use Disorders

Date: April 5, 2023

Time: 2:00 PM to 2:45 PM

Agenda: To review and evaluate contract proposals

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Marisa Srivareerat, Ph.D.
Scientific Review Officer
Scientific Review Branch
Office of Extramural Policy
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 435-1258
marisa.srivareerat@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 6, 2023.

Melanie J. Pantoja,
Program Analyst,
Office of Federal Advisory Committee Policy.

[FR Doc. 2023-02788 Filed: 2/8/2023 8:45 am; Publication Date: 2/9/2023]